Biomedical Engineering Reference
In-Depth Information
O'Reilley K (2006) AMA Opt-Out program will keep prescribing data from drug reps: the associa-
tion plans to track closely physician complaints about drug reps who use data to pressure them.
http://www.ama-assn.org/amednews/2006/05/22/prl10522.htm
.
Accessed July 15, 2011
Oliver C (1991) Strategic responses to institutional processes. Acad Manage Rev 16(1):145-179
Oliver R, Van Horn L (2004) Persistence in prescriptions of branded drugs. Int J Ind Organ
22:523-540
Orentlicher D (2010) Prescription data mining and the protection of patients' interests. J Law Med
Ethics 38(1):74-84
Parsons T (1956) Suggestions for a sociological approach to the theory of organizations. Adm Sci
Q 1(1):63-85
Parsons T (1968) The distribution of power in American society. In: Domhoff W, Ballard H (eds)
C. Wright Mills and the power elite. Beacon, Boston, pp 199-225
Petersen M (2003) Astrazeneca pleads guilty in cancer medicine scheme.
http://www.nytimes.
5088andpartner=rssnytandemc=rss&_r=0
.
Accessed May 16, 2008
Porac JF, Thomas H, Baden-Fuller C (1989) Competitive groups as cognitive communities: the
case of Scottish knitwear manufacturers. J Manage Stud 26(4):397-416
Prahalad CK, Bettis RA (1986) The dominant logic: a new linkage between diversity and perfor-
mance. Strat Manage J 7(6):485-501
Psaty BM, Kronmal RA (2008) Reporting mortality fi ndings in trials of Rofecoxib for Alzheimer
disease or cognitive impairment: a case study based on documents from Rofecoxib litigation.
J Am Med Assoc 299(15):1813-1817
Rao RS, Chandy RK, Prabhu JC (2008) The fruits of legitimacy: why some new ventures gain
more from innovation than others. J Market 72:58-75
Relman AS (2001) Separating continuing medical education from pharmaceutical marketing.
J Am Med Assoc 285(15):2009-2012
Ross JS, Hill KP, Egilman DS, Krimholz HM (2008) Guest authorship and ghostwriting in publi-
cations related to Rofecoxib: a case study of industry documents from Rofecoxib litigation.
J Am Med Assoc 299(15):1800-1812
Ruef M, Scott RW (1998) A multidimensional model of organizational legitimacy: hospital
survival in changing institutional environments. Adm Sci Q 43(4):877-904
Saul S (2006) Sales pitch for treatment.
http://nytimes.com/2006/12/01/business/01beamside.htm
l?scp=2andsq=Saulandst=nyt
.
Accessed Jan 15, 2007
Scott RW (1987) Organizations: rational, natural, and open systems. Prentice-Hall, New Jersey
Scott RW (2001) Institutions and organizations. Sage, Thousand Oaks, GA
Shapiro SP (1987) The social control of impersonal trust. Am J Sociol 93(3):623-658
Shapiro SP (2005) Agency theory. Ann Rev Sociol 31(1):263-284
Singh J, Jayanti RK (2013) When institutional work backfi res: organizational control of profes-
sional work in the pharmaceutical industry. J Manage Stud 50(5):900-929
Starr P (1982) The social transformation of American medicine. Basic topics, New York
Steinbrook RL (2006) For sale: physicians' prescribing data. N Engl J Med 354:2745-2747
Steinbrook RL (2008) Financial support of continuing medical education. J Am Med Assoc
299(9):1060-1062
Steinman MA, Baron RB (2007) Is continuing medical education a drug-promotion tool? Can Fam
Phys 53(10):1650-1653
Steinman MA, Bero LA, Chren MM, Landefeld CS (2006) Narrative review: the promotion of
Gabapentin: an analysis of internal industry documents. Ann Intern Med 145(4):284-293
Stern RN, Barley SR (1996) Organizations and social systems: organization theory's neglected
mandate. Adm Sci Q 41(1):146-162
Studdert DM, Mello MM, Brennan TA (2004) Financial confl icts of interest in Physicians' rela-
tionships with the pharmaceutical industry. N Engl J Med 351(18):1891-1900
Suchman MC (1995) Managing legitimacy: strategic and institutional approaches. Acad Manage
Rev 20(3):571-610
Search WWH ::
Custom Search